MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jiph.2024.04.016

Медицинская библиотека · Journal of infection and public health · 2024

The risk of tuberculosis infection in Saudi patients receiving adalimumab, etanercept, and tocilizumab therapy.

Boqaeid Abdulaziz, Layqah Laila, Alonazy Amgad, Althobaiti Mutaz, Almahlawi Al-Zahraa, Al-Roqy Abdullah, Baharoon Omar, Alsaeedi Abdullah, Shamou Jinan, Baharoon Salim

СтатьяПеревод в очереди

Аннотация

BACKGROUND

The risk of infection including tuberculosis (TB) infection or reactivation during biological therapy with the current various clinical application is a major concern. This risk may be higher in countries endemic to TB. Our aim of this study is to determine the risk of TB infection in patients receiving 3 biological treatments, Adalimumab, Etanercept and Tocilizumab.

METHODS

A retrospective cohort study extending over 2 years follow-up for all patients receiving Adalimumab, Etanercept and Tocilizumab for various clinical indications in a tertiary care center in Saudi Arabia.

RESULT: Over the period of 2015-2019, A total of 410 patients received Adalimumab, 271 received Etanercept and 58 patients received Tocilizumab. Rheumatoid arthritis was the most common indication for therapy in all groups and for Adalimumab the most common indication was inflammatory bowel disease, for Etanercept was psoriatic arthritis and for Tocilizumab was juvenile idiopathic arthritis. After a mean follow up period of 36 ± 8.9 months for patients receiving Adalimumab, 21.5 ± 8.4 months for patients receiving Etanercept and 21 ± 2.5 months for patients receiving Tocilizumab there were no reported cases of TB infection in all groups. Only one patient was diagnosed with latent TB 7 months later after starting Adalimumab and tow patients after starting Etanercept. The overall Interferon Gamma Release Assays (IGRA) positivity rate was 9.7%. There was significant association between IGRA positivity rate and patient age. The cutoff age in which IGRA positivity has significantly increased was 53.20 years.

CONCLUSION

In our study, patients receiving Etanercept, Adalimumab and Tocilizumab had no increased risk of TB infection. Only 0.3% of patients treated with Adalimumab and 0.9% of patients treated with Etanercept converted to a positive IGRA during therapy.

Для цитирования: Boqaeid Abdulaziz, Layqah Laila, Alonazy Amgad, Althobaiti Mutaz, Almahlawi Al-Zahraa, Al-Roqy Abdullah, Baharoon Omar, Alsaeedi Abdullah, Shamou Jinan, Baharoon Salim. The risk of tuberculosis infection in Saudi patients receiving adalimumab, etanercept, and tocilizumab therapy.. Journal of infection and public health. 2024. DOI: 10.1016/j.jiph.2024.04.016.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.